Financing channel feed – Endpoints News

Financing channel feed

Following ASCO showing, Bert Vogelstein’s latest startup launches into recurrent cancer detection

3 years ago

A rare biotech IPO lands on Nasdaq, boosted by RA Capital and a former Eli Lilly drug

3 years ago

Can an oncolytic virus therapy challenge the standard of care in bladder cancer? CG Oncology has $120M to find out

3 years ago

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

3 years ago

Roche doubles down on Jnana's drug discovery platform, kicking off second deal with $50M cash — while biotech bags $107M

3 years ago

RA Capital jumps aboard nine-figure round for the endocrine biotech co-founded by Humalog inventor

3 years ago

Metabolics biotech secures humble Series A from big-name investors

3 years ago

Biohaven claims $300M+ public offering as company charts new journey after Pfizer buyout

3 years ago

Oral alternative to eye injections? Novo backs startup’s big plan to repurpose shelved drug

3 years ago

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup

3 years ago

While PhIII Parkinson's trials go slower than expected, Cerevel previews plans to raise $900M

3 years ago

Scoop: A SoftBank-backed biotech raises more funds after bagging $100M+ for fungi mining

3 years ago

Mining from plants and fungi, CNS startup takes leap into psychoactive drugs — complete with $30M to kick things off

3 years ago

Kura Oncology secures up to $150M in Bristol Myers equity investment, loan from Hercules Capital

3 years ago

'Rulebook of microbial ecology': Pianists launch Concerto to treat eczema, protect crops and get rid of BO

3 years ago

Exclusive: Mt. Everest almost got in the way of a tRNA biotech, but hC Bioscience climbs to Series A extension

3 years ago

Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C

3 years ago

A Chicago biotech skips the IPO in favor of late-stage Series D for a PhIII Tourette drug

3 years ago

Mysterious OrbiMed-backed biotech nears $100M in funding, hints at plans to go after ‘undruggable 3.0’

3 years ago

An NK cell therapy biotech pulls IPO ambitions weeks after second trial clearance

3 years ago

Leading a $60M launch round, RA Capital backs another 'toad venom' startup

3 years ago

Betting on CD47 as others ditch the target, ALX borrows up to $100M to push sole clinical drug forward

3 years ago

Updated: Samsara backs ex-Gilead duo's amalgamation of NASH, liver drug assets from former employer, other biopharmas

3 years ago

That secretive ARCH biotech with two antibodies from MorphoSys? It’s now got $120M

3 years ago

First page Previous page 44 45 464748 49 50 Next page Last page